L. A. ERF, M.D.; L. W. TUTTLE; J. H. LAWRENCE, M.D.
This content is PDF only. Please click on the PDF icon to access.
Previous studies19, 20, 21, 22, 34, 35 have shown that radiophosphorus (15P32) (which owes its radioactivity to the spontaneous emission of beta rays) when administered in the form of sodium phosphate, at first concentrates in the bone marrow and those tissues infiltrated with leukemic cells and later concentrates in the osseous tissues. Radio-phosphorus has been used as a therapeutic agent during the past three years in all types of leukemia, with encouraging results. The principal advantages offered by radio-phosphorus appear to lie in its ease of administration (it may be given orally, intravenously, etc.), in its therapeutic effectiveness and in
ERF LA, TUTTLE LW, LAWRENCE JH. CLINICAL STUDIES WITH THE AID OF RADIO-PHOSPHORUS. IV. THE RETENTION IN BLOOD, THE EXCRETION AND THE THERAPEUTIC EFFECT OF RADIO-PHOSPHORUS ON PATIENTS WITH LEUKEMIA*. Ann Intern Med. 1941;15:487–543. doi: https://doi.org/10.7326/0003-4819-15-3-487
Download citation file:
Published: Ann Intern Med. 1941;15(3):487-543.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use